I appreciate the update, but i'm feeling really wary of this situation. My gut feel is that this virus situation has a long way to play out and that things could get much worse, before they get better. Technically, our SP is not exactly in a position of strength right now, and this may be a harmful event for FLC in the short term - something holders ill-deserve.
The admission that H1 revenue may shift to H2 leaves me, after years of this, thinking that H2 revenue may then slide into 2021 and so on. This situation isn't managements fault of course, but still a concern. I'm struggling to decide what to do...take some off the table in the hope of buying back cheaper? Double down at these prices? Do nothing? I've been considering all of these lol. I'll probably go with option 3.
It's very hard to believe that this won't have a significant impact on iTest's operations at least. Not long-term, but the chances of them raising their orders or even continuing at 2019 pace in 2020 would appear to be unlikely. The market doesn't appear delighted by the IC revenue (low margin as it is) so where does that leave 2020 growth? We were looking at China weren't we? We need their MABR and SUBRE contracts, and it's hard to see those coming until this virus situation is under control.
Who'd be an investor?!
FLC Price at posting:
34.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)